Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 22, 2013, Pages 6156-6160

  Sangthong, Supranee ^a   Ha, Helen ^b   Teerawattananon, Thapong ^a   Ngamrojanavanich, Nattaya ^a   Neamati, Nouri ^b   Muangsin, Nongnuj ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anthraquinone derivatives; Cytotoxic mechanism; Doxorubicin resistance

Indexed keywords

4 (4 AMINOBENZYLAMINO) 9,10 DIOXO 9,10 DIHYDROANTHRACEN 1 YL 4 METHYLBENZENESULFONIC ACID; ANTHRACENE 9,10 DIONE DERIVATIVE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; IC 50; IN VITRO STUDY;

ANTHRAQUINONE DERIVATIVES; CYTOTOXIC MECHANISM; DOXORUBICIN-RESISTANCE;

ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS;

EID: 84885957351     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.09.004     Document Type: Article

References (27)

1. F.M. Muggia, and M.D. Green Crit. Rev. Oncol. Hematol. 11 1991 43
2. R.L. Momparler, M. Karon, S.E. Siegel, and F. Avila Cancer Res. 36 1976 2891
3. M. Agbandje, T.C. Jenkins, R. McKenna, A.P. Reszka, and S. Neidle J. Med. Chem. 35 1992 1418
4. R.E. McKnight, J. Zhang, and D.W. Dixon Bioorg.Med. Chem. Lett. 14 2004 401
5. T. Fojo, and H.M. Coley Clin. Breast Cancer 7 2007 749
6. Y. Octavia, C.G. Tocchetti, K.L. Gabrielson, S. Janssens, H.J. Crijins, and A. Moens J. Mol. Cell. Cardiol. 52 2012 1213
7. Q. Huang, G. Lu, H.M. Shen, M.C. Chung, and C.N. Ong Med. Res. Rev. 27 2007 609
8. G. Srinivas, S. Babykutty, P.P. Sathiadevan, and P. Srinivas Med. Res. Rev. 27 2007 591
9. L. Zhang, and M.C. Hung Oncogene 12 1996 571
10. W. Wang, Y.P. Sun, X.Z. Huang, M. He, Y.Y. Chen, G.Y. Shi, H. Li, J. Yi, and J. Wang Biochem. Pharmacol. 79 2010 1134
11. J. Cai, X. Niu, Y. Chen, Q. Hu, G. Shi, H. Wu, J. Wang, and J. Yi Neoplasia 10 2008 41
12. J. Yang, H. Li, Y.Y. Chen, X.J. Wang, G.Y. Shi, Q.S. Hu, X.L. Kang, Y. Lu, X.M. Tang, Q.S. Guo, and J. Yi Free Radical Biol. Med. 37 2004 2027
13. J. Yi, J. Yang, R. He, F. Gao, H. Sang, X. Tang, and R.D. Ye Cancer Res. 64 2004 108
14. J. Ruiz, C.D. Vicente, C. Haro, and A. Espinosa Inorg. Chem. 50 2011 2151
15. W. Ke, P. Yu, J. Wang, R. Wang, C. Guo, L. Zhou, C. Li, and K. Li Med. Oncol. 28 Suppl 1 2011 S135
16. H.Y. Tu, A.M. Huang, C.H. Teng, T.C. Hour, S.C. Yang, Y.S. Pu, and C.N. Lin Bioorg. Med. Chem. 19 2011 5670
17. P. Suboj, S. Babykutty, P. Srinivas, and S. Gopala Pharmacology 89 2012 91
18. H. Cui, A. Schroering, and H.F. Ding Mol. Cancer Ther. 1 2002 679
19. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Cancer Res. 47 1987 943
20. A. Munshi, M. Hobbs, and R.E. Meyn Methods Mol. Med. 110 2005 21
21. A.G. NiedziaZielske J. Org. Chem. 52 1987 1305
22. Y.Y. Liu, G.A. Patwardhan, K. Bhinge, V. Gupta, X. Gu, and S.M. Jazwinski Cancer Res. 71 2011 2276
23. B. Ogretmen, and A.R. Safa Oncogene 14 1997 499
24. D. Katz, E. Ito, K.S. Lau, J.D. Mocan, C. Bastianutto, A.D. Schimmer, and F.F. Liu BioTechn. Preclin. Dev. 44 2008 Pix
25. M.T. Kuo Antioxid. Redox Signaling 11 2009 99
26. Z.H. Siddik Oncogene 22 2003 7265
27. A.M. Deffie, T. Alam, C. Seneviratne, S.W. Beenken, J.K. Batra, T.C. Shea, W.D. Henner, and G.J. Goldenberg Cancer Res. 48 1988 3595